You are here

Joe Jimenez

Joe Jimenez's Aditum finds fresh twist on old idea, paying $10M for autoimmune BTK inhibitor

Fierce Biotech

Fri, 04/28/23 - 10:00 am

venture capital

autoimmune disease

Aditum Bio Announces Formation of Ancora Bio, to Focus on Treatment-Resistant Depression

BioSpace

Wed, 06/30/21 - 10:58 am

treatment-resistant depression

Novartis alums Jimenez, Fishman unveil their next act: Aditum Bio

Fierce Biotech

Mon, 11/2/20 - 10:18 am

Life after Novartis: Jimenez joins board of Bayer-backed cell therapy startup

Fierce Biotech

Tue, 01/28/20 - 11:03 am

Century Therapeutics

Microbiome player uBiome puts founders on leave, interim CEO promises to assist in federal probe

Endpoints

Wed, 05/1/19 - 11:42 pm

Ex-Novartis Chief Joins uBiome to Help Launch Discovery and Development Business

CP Wire

Fri, 09/21/18 - 09:38 am

Ex-Novartis Chief Joins uBiome to Help Launch Discovery and Development Business

Fri, 09/21/18 - 09:28 am

CEO interrupted: Novartis chief Narasimhan looks to new ethics czar to clean up after the lingering Cohen mess

Endpoints

Tue, 08/14/18 - 11:25 am

Vasant Narasimham

Novartis, Michael Cohen contacts were more extensive than previously disclosed

Stat

Fri, 07/13/18 - 12:00 pm

Cohen scandal disrupts ex-Novartis CEO's move to hedge fund board: WSJ

Fierce Pharma

Tue, 05/22/18 - 06:09 pm

Former Novartis CEO Explains Why His Company Paid Trump Lawyer Michael Cohen $1.2 Million

Forbes

Wed, 05/16/18 - 11:04 am

Drugmaker Novartis plays down its deal with Trump’s lawyer, tying it to its former CEO

Marketwatch

Wed, 05/9/18 - 09:18 am

Vasant Narasimham

Joe Jiménez, Novartis outgoing CEO, describes group’s strategy

GoinPharma

Thu, 02/1/18 - 09:27 am

Big day looming, Novartis’ new CEO Vas Narasimhan readies his jump into a marketing melee

Endpoints

Wed, 01/24/18 - 09:16 am

P&G investors wish for CEO Joe Jimenez as outgoing Novartis chief joins board

Fierce Pharma

Tue, 12/19/17 - 10:20 am

Departing Novartis CEO Sets His Eyes On Silicon Valley

Forbes

Thu, 09/7/17 - 09:51 am

Novartis follows up on big CAR-T win by naming Vas Narasimhan as its new CEO

Endpoints

Mon, 09/4/17 - 10:13 am

Novartis CEO: Here's How We Handled A Milestone In Pediatric Cancer

Forbes

Fri, 09/1/17 - 04:08 pm

pediatric cancer

Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?

Forbes

Wed, 08/30/17 - 11:53 pm

acute lymphoblastic leukemia

Novartis CEO opens door to cancer patient demanding ‘fair’ CAR-T pricing

Fierce Pharma

Tue, 08/22/17 - 12:05 am

Pages